Why the study?
Is losartan effective and well-tolerated for lowering blood pressure compared to ACE inhibitors and placebo in patients with high blood pressure?
Is losartan effective and well-tolerated for lowering blood pressure compared to ACE inhibitors and placebo in patients with high blood pressure?
Answers are grounded in this paper and cite their sources.
Losartan represents a promising new class of antihypertensive agents that provides effective blood pressure reduction without the cough associated with ACE inhibitors.
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by the stimulation of the AT1 subtype of the angiotensin II receptor. This agent, at doses of 50-150mg/day, is as effective at lowering blood pressure as chronic angiotensin converting enzyme (ACE) inhibitors. Losartan is generally well tolerated and has an incidence of adverse effects very similar, in double-blind controlled trials, to that of placebo. It does not cause coughing, the most common side-effect of the ACE inhibitors, most probably because angiotensin II antagonism has no impact on ACE, an enzyme known to process bradykinin and other cough-inducing peptides. Losartan is a promising antihypertensive agent with the potential to become a first-line option for the treatment of patients with high blood pressure.
No takes yet. Share an insight, caveat, or question.
Waeber et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: